Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial

Additional Metadata
Persistent URL	doi.org/10.1016/S1470-2045(15)70025-2, hdl.handle.net/1765/91638
Journal	The Lancet Oncology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Petrylak, D.P, Vogelzang, N.J, Budnik, N, Wiechno, P.J, Sternberg, C.N, Doner, K, … Fizazi, K. (2015). Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. doi:10.1016/S1470-2045(15)70025-2

Publication